摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

[(2R,3S,4E,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4-(fluoromethylidene)-3-hydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate | 177956-38-6

中文名称
——
中文别名
——
英文名称
[(2R,3S,4E,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4-(fluoromethylidene)-3-hydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate
英文别名
——
[(2R,3S,4E,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-4-(fluoromethylidene)-3-hydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate化学式
CAS
177956-38-6
化学式
C10H14FN3O10P2
mdl
——
分子量
417.18
InChiKey
VUPKAWMDMNMTNL-ASKVSEFXSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    746.1±70.0 °C(Predicted)
  • 密度:
    2.16±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -5
  • 重原子数:
    26
  • 可旋转键数:
    6
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    201
  • 氢给体数:
    5
  • 氢受体数:
    11

文献信息

  • Nucleotide mimics and their prodrugs
    申请人:——
    公开号:US20040059104A1
    公开(公告)日:2004-03-25
    The present invention relates to nucleoside diphosphate mimics and nucleoside triphosphate mimics, which contain diphosphate or triphosphate moiety mimics and optionally sugar-modifications and/or base-modifications. The nucleotide mimics of the present invention, in a form of a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutical formulation, are useful as antiviral, antimicrobial, and anticancer agents. The present invention provides a method for the treatment of viral infections, microbial infections, and proliferative disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of the present invention optionally in combination with other pharmaceutically active agents.
    本发明涉及核苷二磷酸模拟物和核苷三磷酸模拟物,其中包含二磷酸或三磷酸基团模拟物,以及可选的糖修饰和/或碱基修饰。本发明的核苷酸模拟物,以药学上可接受的盐、药学上可接受的前药或药物配方的形式,可用作抗病毒、抗微生物和抗癌剂。本发明提供了一种治疗病毒感染、微生物感染和增生性疾病的方法。本发明还涉及包含本发明化合物的药物组合物,可选地与其他药理活性剂结合。
  • Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs
    申请人:Drug Innovation & Design, Inc.
    公开号:US20030138432A1
    公开(公告)日:2003-07-24
    The present invention relates to the compositions, methods, and applications of a novel approach to selective cellular targeting. The purpose of this invention is to enable the selective delivery and/or selective activation of effector molecules to target cells for diagnostic or therapeutic purposes. The present invention relates to multi-functional prodrugs or targeting vehicles wherein each functionality is capable of enhancing targeting selectivity, affinity, intracellular transport, activation or detoxification. The present invention also relates to ultra-low dose, multiple target, multiple drug chemotherapy and targeted immunotherapy for cancer treatment.
    本发明涉及一种新的选择性细胞靶向的组合物、方法和应用。本发明的目的是为了实现对目标细胞的选择性输送和/或选择性激活效应分子,以进行诊断或治疗。本发明涉及多功能前药或靶向载体,其中每个功能都能增强靶向选择性、亲和力、细胞内转运、激活或解毒。本发明还涉及超低剂量、多靶点、多药物化疗和靶向免疫疗法,用于癌症治疗。
  • SELECTIVE CELLULAR TARGETING: MULTIFUNCTIONAL DELIVERY VEHICLES
    申请人:Drug Innovation & Design, Inc.
    公开号:EP1255567A1
    公开(公告)日:2002-11-13
  • US7285658B2
    申请人:——
    公开号:US7285658B2
    公开(公告)日:2007-10-23
  • US7598230B2
    申请人:——
    公开号:US7598230B2
    公开(公告)日:2009-10-06
查看更多